LONDON, June 11, 2015 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of IXICO
Highlights of the analysis on IXICO by Edison's healthcare analysts Hans Bostrom and Christian Glennie are as follows:
Established in 2004, IXICO offers medical imaging technologies and services to pharma companies and healthcare service providers. Its digital technologies aim to improve the diagnosis as well as treatment outcomes of diseases of the brain, notably dementia. It has 52 employees.
IXICO sells technologies and services for the analysis of brain disease. We expect strong growth mainly driven by the expansion of its clinical trial business into new indications, new markets and bigger contracts. It is also well placed to capitalise on the burgeoning use of digital technologies in disease management. Using DCF, we value IXICO at £10.7m or 62p/share.
To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support their capital markets activities. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
For more information please contact:
Hans Bostrom Edison Investment Research +44 (0)20 3681 2522
Christian Glennie Edison Investment Research +44 (0)20 3077 5727
SOURCE Edison Investment Research